Predicine宣布与Apollomics合作,开发针对非小细胞肺癌 (NSCLC) 的CDx伴随诊断检测方案

Predicine Announces the collaboration with Apollomics on the PredicineCARE™ Blood cfDNA NGS assay as a companion diagnostic (CDx) development for non-small cell lung cancer (NSCLC) patients

Collaboration Utilizing PredicineCARE™ Blood cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alterations in Lung Cancer.

基于血液的PredicineCARE™ Blood cfDNA NGS Assay的伴随诊断(CDx)合作标志着无创伤基因变异检测在肺癌临床诊疗中的开创性进展。


HAYWARD, Calif., April 05, 2024 /GLOBE NEWSWIRE/ – Predicine, Inc., a leading molecular insights company, today announced a collaboration with Apollomics, Inc. This collaboration aims to advance the development of PredicineCARE™, a blood cell-free DNA (cfDNA) next-generation sequencing (NGS) assay, to identify non-small cell lung cancer (NSCLC) patients who may benefit from targeted therapy.

HAYWARD, Calif., April 05, 2024 /GLOBE NEWSWIRE/ ——行业领先的分子诊断公司 Predicine, Inc. 今天宣布与Apollomics, Inc达成伴随诊断(CDx)合作,此次合作将围绕PredicineCARE™ Blood cfDNA NGS Assay开展,以鉴别具有特定基因变异的非小细胞肺癌患者,帮助获取更精准的靶向治疗方案。


PredicineCARE™ was granted Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration on August 23, 2022. PredicineCARE™ is a comprehensive, state-of-the-art NGS assay that interrogates point mutations/indels, fusions, amplifications, and gene deletions in key cancer-associated genes using cfDNA from liquid biopsy samples such as blood and urine.

PredicineCARE™检测方法已于 2022 年 8 月 23日获得美国食品药品监督管理局(FDA)颁发的突破性医疗器械认定 (BDD),可利用血液、尿液等液体活检样本中的 cfDNA 检测癌症关键基因的点突变(SNV)、插入和缺失(InDel)、融合(Fusion)、扩增(Amplifications)和基因缺失(Gene deletions)。


Dr. Shidong Jia, Predicine’s Founder, Chairman, and CEO, said in a statement. “we are pleased to collaborate with Apollomics on the co-development of a cfDNA blood-based assay designed to identify patients with NSCLC harboring actionable cancer variants who may benefit from targeted therapy.”



About PredicineCARE™ Blood cfDNA Assay

The PredicineCARE™ Blood cfDNA assay is a targeted NGS test that enables detection of genomic alterations, including single nucleotide variants (SNVs), insertions and deletions (Indel), fusions, and copy number variations in cfDNA.

关于 PredicineCARE™ Blood cfDNA Assay

PredicineCARE™ Blood cfDNA Assay是一款基于二代测序(NGS)技术,分析肿瘤患者血液样本中游离DNA(cfDNA)的肿瘤体细胞变异检测产品。基于目标区域捕获技术,全面涵盖肿瘤相关基因,检测变异类型包括单核苷酸变异 (SNV)、插入和缺失 (Indel)、融合(Fusion)和拷贝数变异(CNVs)。


About Predicine 

Predicine is a leading molecular insights company committed to advancing precision medicine in oncology. Predicine has developed a proprietary cell-free DNA and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The Predicine portfolio comprises state-of-the-art blood, urine, and tissue-based Next-Generation Sequencing (NGS) assays designed for harmonized global use in research, clinical development, companion diagnostic (CDx) development, and patient testing. With operational hubs in Silicon Valley, Houston, Chicago, and Shanghai, Predicine collaborates with leading biopharma companies, institutions, and governments in personalized healthcare on a global scale. For more information, please visit us on and follow us on LinkedIn or Twitter (X).

Predicine 介绍

Predicine是一家行业领先的分子诊断公司,致力于推进肿瘤学领域的精准医疗。我们致力于开发独特的cfDNA+cfRNA 联合液体活检技术,涵盖疾病管理的各个阶段:包括分子诊断、治疗选择、治疗反应评估、微小残留病灶(MRD)监测和早期癌症检测。Predicine 系列产品包括最先进的基于血液、尿液和组织的新一代测序(NGS) 检测方法,用于全球标准一致的临床试验和伴随诊断 (CDx) 开发。在硅谷、休斯顿、芝加哥、上海、北京和苏州设有运营中心。Predicine 与国际顶尖的制药公司、医疗机构和政府合作,在个性化医疗健康领域开展大规模合作。了解更多信息请访问我们的网站, 访问LinkedIn或 Twitter (X)。

Contact Information:
Predicine, Inc.

Leave a Reply